Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties

Cell Cycle

Volumn 14, Issue 22, 2015, Pages 3527-3532

  Cuyàs, Elisabet ^a,b   Martin Castillo, Begoña ^a,b   Corominas Faja, Bruna ^a,b   Massaguer, Anna ^c   Bosch Barrera, Joaquim ^a,b   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c UNIVERSITY OF GIRONA   (Spain)

Author keywords

Antibiotics; Basal like; Biolog; Breast cancer; Cancer stem cells; Claudin low; Drug repositioning; Drug repurposing; Phenotype; Ribosomes

Indexed keywords

ACRIFLAVINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; CLAUDIN; CYCLOHEXIMIDE; DACTINOMYCIN; DAUNORUBICIN; EMETINE; MICROBICIDE; PUROMYCIN; RIBOSOME PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN SYNTHESIS INHIBITOR;

ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CHEMOSENSITIVITY; HUMAN; PROTEIN SYNTHESIS; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; DRUG REPOSITIONING; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SCREENING; MAMMARY GLAND; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; PHENOTYPE; RIBOSOME; TUMOR CELL LINE;

ACRIFLAVINE; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOHEXIMIDE; DACTINOMYCIN; DRUG REPOSITIONING; EMETINE; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MAMMARY GLANDS, HUMAN; MICROARRAY ANALYSIS; NEOPLASTIC STEM CELLS; PHENOTYPE; PROTEIN BIOSYNTHESIS; PROTEIN SYNTHESIS INHIBITORS; PUROMYCIN; RIBOSOMES;

EID: 84959282501     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2015.1044173     Document Type: Article

References (33)

1. Lamb R, Harrison H, Smith DL, Townsend PA, Jackson T, Ozsvari B, Martinez-Outschoorn UE, Pestell RG, Howell A, Lisanti MP, et al. Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. Oncotarget 2015; 6:4585-601.
2. PMID;25671304; DOI: 10.18632/oncotarget.3278.
3. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol 2008; 26:2813-20; PMID:18539959; http://dx.doi.org/10.1200/JCO.2008.16.3931.
4. Scheel C, Weinberg RA. Cancer stem cells and epithelial- mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012; 22:396-403; PMID:22554795; http://dx.doi.org/10.1016/j. semcancer.2012.04.001.
5. Marjanovic ND, Weinberg RA, Chaffer CL. Cell plasticity and heterogeneity in cancer. Clin Chem 2013; 59:168-79; PMID:23220226; http://dx.doi.org/10.1373/clinchem.2012.184655.
6. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013; 501:328-37; PMID:24048065; http://dx.doi.org/10.1038/nature12624.
7. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells - what challenges do they pose? Nat Rev Drug Discov 2014; 13:497-512; PMID:24981363; http://dx.doi.org/10.1038/nrd4253.
8. Chaffer CL, Weinberg RA. How does multistep tumorigenesis really proceed? Cancer Discov 2015; 5:22-4; PMID:25583800; http://dx.doi.org/10.1158/2159- 8290.CD-14-0788.
9. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 2012; 109:2724-9; PMID:22003129; http://dx.doi.org/10.1073/pnas.1018854108.
10. Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, et al. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res Treat 2013; 142:237-55; PMID:24162158; http://dx.doi. org/10.1007/s10549-013-2743-3.
11. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5-23; PMID:21147047; http://dx.doi.org/10.1016/j. molonc.2010.11.003.
12. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12: R68; PMID:20813035; http://dx.doi.org/10.1186/bcr2635.
13. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois- Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012; 8: e1002723; PMID:22654675; http://dx.doi.org/10.1371/journal.pgen.1002723.
14. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A 2009;106:13820-5; PMID:19666588; http://dx.doi. org/10.1073/pnas.0905718106.
15. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. A core MYC gene expression signature is prominent in basallike breast cancer but only partially overlaps the core serum response. PLoS One 2009; 4:e6693; PMID:19690609; http://dx.doi.org/10.1371/journal.pone.0006693.
16. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014; 124:398-412; PMID:24316975; http://dx.doi. org/10.1172/JCI71180.
17. Liu JC, Voisin V, Wang S, Wang DY, Jones RA, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med 2014; 6:1542-60; PMID:25330770; http://dx.doi.org/10.15252/emmm.201404402.
18. Ghosh S, Varela L, Sood A, Park BH, Lotan TL. mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Res 2013; 73:5218-31; PMID:23774212; http://dx.doi.org/10.1158/0008- 5472.CAN-13-0429.
19. Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon- Christersson J, Osoegawa K, de Jong P, Oredsson S, Ringnér M, Höglund M, et al. Highresolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007; 46:543-58; PMID:17334996; http://dx.doi. org/10.1002/gcc.20438.
20. Oliveras-Ferraros C, Vazquez-Martin A, Martin- Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin). Biochem Biophys Res Commun 2010; 397:27-33; PMID:20470755; http://dx.doi.org/10.1016/j. bbrc.2010.05.041. www.
21. Oliveras-Ferraros C, Vazquez-Martin A, Martin- Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA. Pathway-focused proteomic signatures in HER2- overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin). Int J Oncol 2010;37:669-78; PMID:20664936.
22. Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Torres-Garcia VZ, Sauri-Nadal T, Barco SD, Lopez-Bonet E, Brunet J, Martin-Castillo B, Menendez JA. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochem Biophys Res Commun 2011; 407:412-9; PMID:21402055; http://dx. doi.org/10.1016/j.bbrc.2011.03.039.
23. Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Vellon L, Menendez JA. Autophagy positively regulates the CD44(C) CD24(-/low) breast cancer stem-like phenotype. Cell Cycle 2011 Nov 15;10:3871-85; http://dx.doi.org/10.4161/cc.10.22.17976.
24. Cufí S, Corominas-Faja B, Vazquez-Martin A, Oliveras- Ferraros C, Dorca J, Bosch-Barrera J, Martin- Castillo B, Menendez JA. Metformin-induced preferential killing of breast cancer initiating CD44CCD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2C human breast cancer xenografts. Oncotarget 2012;3:395-8; PMID:22565037.
25. Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufí S, Moreno JM, Corominas-Faja B, Urruticoechea A, Martín AG, López-Bonet E, Menendez JA. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle 2013; 12:225-45; PMID:23255137; http://dx.doi.org/10.4161/cc.23274.
26. Wong W, Bai XC, Brown A, Fernandez IS, Hanssen E, Condron M, Tan YH, Baum J, Scheres SH. Cryo-EM structure of the Plasmodium falciparum 80S ribosome bound to the anti-protozoan drug emetine. Elife 2014; 3; http://dx.doi.org/10.7554/eLife.03080.
27. Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1b through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11:1008-16; PMID:21464611; http://dx.doi.org/10.4161/cbt.11.12.15540.
28. Parmar N, Wetton N, Alvarado S, Kennedy S. Profiling of human normal and cancer cell lines using phenotype microarray analysis. FASEB J 2014; 28:613.5.
29. Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer 2010; 10:254-66; PMID:20332778; http://dx.doi.org/10.1038/nrc2824.
30. van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer 2010; 10:301-9; PMID:20332779; http://dx.doi.org/10.1038/nrc2819.
31. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3:673-83; PMID:15286734; http://dx.doi.org/10.1038/nrd1468.
32. Vazquez-Martin A, López-Bonetc E, Cufí S, Oliveras- Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in premalignant lesions. Drug Resist Updat 2011; 14:212-23; PMID:21600837; http://dx.doi.org/10.1016/j.drup.2011.04.003.
33. Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, et al. A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther 2011; 10:1818-1828; PMID:21859839; http://dx.doi.org/10.1158/1535-7163.MCT-11-0268.